NYSE - Delayed Quote USD

Novartis AG (NVS)

97.44 -1.62 (-1.64%)
At close: 3:59 PM EDT
97.44 0.00 (0.00%)
After hours: 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
47,733,000.00
46,660,000.00
43,461,000.00
43,974,000.00
49,898,000.00
Cost of Revenue
12,577,000.00
12,472,000.00
11,582,000.00
11,735,000.00
15,121,000.00
Gross Profit
35,156,000.00
34,188,000.00
31,879,000.00
32,239,000.00
34,777,000.00
Operating Expense
24,632,000.00
24,419,000.00
23,933,000.00
22,183,000.00
24,625,000.00
Operating Income
10,524,000.00
9,769,000.00
7,946,000.00
10,056,000.00
10,152,000.00
Net Non Operating Interest Income Expense
-538,000.00
-419,000.00
-574,000.00
-794,000.00
-812,000.00
Other Income Expense
-254,000.00
-227,000.00
-195,000.00
15,268,000.00
538,000.00
Pretax Income
9,732,000.00
9,123,000.00
7,177,000.00
24,530,000.00
9,878,000.00
Tax Provision
622,000.00
551,000.00
1,128,000.00
1,625,000.00
1,807,000.00
Net Income Common Stockholders
15,245,000.00
14,850,000.00
6,955,000.00
24,021,000.00
8,072,000.00
Diluted NI Available to Com Stockholders
15,245,000.00
14,850,000.00
6,955,000.00
24,021,000.00
8,072,000.00
Basic EPS
7.37
7.15
3.19
10.71
3.55
Diluted EPS
7.33
7.10
3.17
10.63
3.52
Basic Average Shares
2,060,294.14
2,076,794.14
2,181,180.34
2,242,601.17
2,277,000.00
Diluted Average Shares
2,076,000.00
2,092,000.00
2,197,000.00
2,260,000.00
2,296,000.00
Total Operating Income as Reported
10,524,000.00
9,769,000.00
7,946,000.00
10,056,000.00
10,152,000.00
Total Expenses
37,209,000.00
36,891,000.00
35,515,000.00
33,918,000.00
39,746,000.00
Net Income from Continuing & Discontinued Operation
15,245,000.00
14,850,000.00
6,955,000.00
24,021,000.00
8,072,000.00
Normalized Income
9,307,322.65
8,767,876.00
6,204,112.00
22,971,411.00
8,182,295.00
Interest Income
529,000.00
627,000.00
377,000.00
70,000.00
91,000.00
Interest Expense
876,000.00
855,000.00
800,000.00
787,000.00
869,000.00
Net Interest Income
-538,000.00
-419,000.00
-574,000.00
-794,000.00
-812,000.00
EBIT
10,608,000.00
9,978,000.00
7,977,000.00
25,317,000.00
10,747,000.00
EBITDA
18,329,000.00
18,255,000.00
14,682,000.00
30,914,000.00
17,211,000.00
Reconciled Cost of Revenue
12,577,000.00
12,472,000.00
11,582,000.00
11,735,000.00
15,121,000.00
Reconciled Depreciation
7,721,000.00
8,277,000.00
6,705,000.00
5,597,000.00
6,464,000.00
Net Income from Continuing Operation Net Minority Interest
9,107,000.00
8,568,000.00
6,049,000.00
22,908,000.00
8,072,000.00
Total Unusual Items Excluding Goodwill
-214,000.00
-214,000.00
-184,000.00
-69,000.00
-135,000.00
Total Unusual Items
-214,000.00
-214,000.00
-184,000.00
-69,000.00
-135,000.00
Normalized EBITDA
18,543,000.00
18,469,000.00
14,866,000.00
30,983,000.00
17,346,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-13,677.35
-14,124.00
-28,888.00
-5,589.00
-24,705.00
12/31/2020 - 11/7/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AZN AstraZeneca PLC
75.17
+0.19%
 
SNY Sanofi
49.13
-0.47%
 
GSK GSK plc
41.12
+0.50%
 
MRK Merck & Co., Inc.
131.19
+0.36%
 
RHHBY Roche Holding AG
30.27
+0.83%
 
BMY Bristol-Myers Squibb Company
44.85
+0.34%
 
BIIB Biogen Inc.
208.90
+3.18%
 
AMGN Amgen Inc.
269.98
+0.22%
 
ABBV AbbVie Inc.
159.62
-4.58%
 
GILD Gilead Sciences, Inc.
65.42
+0.23%